1/53
Looks like no tags are added yet.
what percentage of the US population will face a diagnosis of cancer during their lifetime
25%
what is chemotherapy
use of drugs to inhibit or kill proliferating cancer cells while leaving host cells unharmed or at least recoverable
what two classes of genes are involved in carcinogenesis
oncogenes
tumor suppressor genes (TP53)
when eradication of cancer is not am option what is considered
control of cancer
stop cancer from enlarging and spreading
extend survival and maintain quality of life
treat as chronic disease
adjuvant therapy
additional treatment given after primary treatment
chemo
radiation
hormone therapy
targeted therapy
biological therapy
neoadjuvant therapy
treatment given as first step to shrink tumor before main treatment; surgery
"induction therapy"
chemo
radiation
hormone therapy
supportive therapy
antiemetics (5HT3)
antibiotics
urate nephropathy (allopurinol)
analgesics
aggressive high dose chemo
dose limiting is toxic to normal cells (rescue therapy)
cyclic regimens for regeneration of normal cells
supportive therapy
what is given for hematotoxicity
bone marrow transplant, hematopoietic growth factors
what is given for MTX toxicity to reduce myelosuppression and mucositis
folate leucovorin
what is given as a detoxifying agent for urotoxicity and hemorrhagic cystitis with cyclophosphamide or ifosfamide
MENSA
what is used as chelating agent for iron and reduced anthracycline cardiotoxicity
dexrazoxane
what reduces hematotoxicity, nephrotoxicity and ototoxicity of cisplatin
amifostine
what is given to enhance efficacy of fluorouracil
leucovorin
cell cycle: G0
resting phase; non dividing
cell cycle: G1
cell grows
cell cycle: S
DNA replication
cell cycle: G2
cell prepares to divide
cell cycle: M
cell division; mitosis
what drug is used for G1
hydrocortisone
what drugs are used for S phase
antimetabolites
- purines
- thymidine
- folate antagonist
what drugs are used for G2
antibiotics
- bleomycin
what drugs are used for M phase
antimitotics
why are combo therapies used
- to enhance curative effects
- decrease toxicity
- reduce drug resistance
advantages of combo therapies
- maximal cell kill within range of tolerated toxicity
- effective for dividing and resting cancer cells
- slow or prevent development of resistance
t/f the aim of combo therapies is to urge more G0 phase cells to enter proliferating cycles to increase the amount of tumor cells killed by drugs
true
high GF tumors
S or M phases drugs used first then non specific to kill other cells then G0 to kill new cells
low GF tumors
solid tumors
non specific drugs used first then specific drugs then G0 phase to kill new cells
what cells are high GF cells
hair, GI, Skin, reproductive and bone marrow
combo of low GF and high GF drugs
does not increase toxicity but has synergism of action
drug resistance
- increased DNA repair
- formation of trapping agents
- changes in target enzymes
- decreased activation of prodrugs
- inactivation of drugs
- decreased drug accumulation
short term toxicity
appears with rapid proliferating cells
- myelosuppression
- GIT symptoms
- alopecia
what drugs does NOT have myelosuppression
bleomycin
vincristine
asparaginase
monoclonal antibodies
tyrosine kinase inhibitors
what drugs have GIT symptoms
cisplatin
cyclophosphamide/ifosfamide
doxorubicin/epirubicin
what drugs have hemorrhagic cystitis
ifosfamide (all doses)
cyclophosphamide (higher doses)
long term toxicity
carcinogenesis
teratogenesis
sterility
cancer drugs classes
antimetabolites
alkylating
natural
hormones
miscellaneous
antimetabolites
inhibit synthesis of DNA or RNA
effects S phase
antifolates
pyrimidine
purines
antimetabolites: antifolates
methotrexate
- inhibits dyhidrofolate reductase
TX:
- ALL
- Burkitts
- breast
- bladder
- head and neck
- RA and Crohns
S/E: myelosuppression, alopecia, liver toxic
antimetabolites: premetrexed
similar to MTX
Tx: non small cell lung cancer
give folic acid as resuce
antimetabolites: purine
mercaptupurine
first used in cancer tx
- ALL and CML
inhibits purine synthesis by inhibiting enzyme HGPRTases
S/E: N/V/D, myelosuppression, liver toxic, anorexia
antimetabolites: pyrimidine
5-FU
-inhibits thymidine synthesis
TX:
breast
colorectal
ovarian
pancreatic
gastric
S/E: diarrhea, myelosuppression, alopecia
antimetabolites: capecitabine
not cytotoxic until converted to 5-FU
TX:
colorectal
breast
S/E: neutropenia, thrombocytopenia, anemia, hand-foot syndrome
alkylating agents are the ___ and ___ used
oldest
most
t/f clinical use evolved from soldiers exposed during WWI to sulfur mustard gas and experienced bone marrow suppression and lymph node shrinkage
true
t/f alkylating agents are cell cycle non specific
true
where is the most common binding site for alkylating agents
@ N-7 on DNA guanine
alkylating: cyclophosphamide
moa: DNA crosslinking (intra or inter) and blocking DNA replication
TX:
breast
ovarian
CLL
non-hodgkins
neuroblastoma
S/E: myelosuppression, alopecia, hemorrhagic cystitis, N/V
what are 2 active agents for cyclophosphamide
4- hydroxycyclophosphamide
aldophosphamide
what are the 2 INactive agents with cyclophosphamide
4-ketocyclophosphamide
carboxyphosphamide
what are the 2 cytotoxic agents with cyclophosphamide
acrolein
phosphoramide mustard
while ifosfamide must be converted to cyclophosphamide, encephalopathy may occur within
48-72 hrs
alkylating: mechlorethamine
TX: Hodgkins and non-Hodgkins
S/E: GI, alopecia, sterility, myelosuppression
alkylating: procarbazine
TX: Hodgkins and non-Hodgkins, brain tumors
S/E: myelosuppression, GI, CNS, peripheral, skin